DEF 14A: DiaMedica Therapeutics Seeks Shareholder Approval for Amended Incentive Plan, Executive Compensation

DiaMedica Therapeutics is asking shareholders to approve an amendment to its 2019 Omnibus Incentive Plan and provide advisory votes on executive compensation at the upcoming Annual General Meeting.

Summary

• DiaMedica Therapeutics is holding its 2024 Annual General Meeting of Shareholders on May 22, 2024.
• Shareholders will vote on several proposals, including the election of seven directors, the appointment of Baker Tilly US, LLP as the independent registered public accounting firm, and an amendment to the 2019 Omnibus Incentive Plan.
• The proposed amendment to the incentive plan would increase the number of shares available by 3,000,000.
• Shareholders will also cast advisory votes on executive compensation and the frequency of future advisory votes on executive compensation.
• The Board of Directors recommends voting FOR all director nominees, the appointment of Baker Tilly, the incentive plan amendment, and the approval of executive compensation, and for a frequency of every ONE YEAR on the say-on-pay vote.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the proposals for the Annual General Meeting. The Board's recommendations are positive, and the company highlights its commitment to good governance and pay-for-performance.

Positives

• The proposed amendment to the incentive plan is intended to attract and retain talent, align director, employee, and shareholder interests, and protect shareholder interests through sound governance practices.
• The company's compensation practices include best practices such as emphasizing pay for performance, structuring executive compensation so a significant portion is at risk, and maintaining a clawback policy.
• The Board is committed to corporate governance best practices, including annual election of directors, regular executive sessions, and independent board committees.

Negatives

• The company lost its emerging growth company status, resulting in new requirements for say-on-pay votes.
• The potential dilution from the proposed share increase under the Amended 2019 Plan is 22.1%.

Risks

• The company faces risks inherent in every business, including regulatory, compliance, legal, competitive, financial, operational, political, cybersecurity, strategic, and reputational risks.
• The company's success depends on attracting, motivating, and retaining qualified personnel in a highly competitive market for employee talent.

Future Outlook

The company expects the additional shares available under the Plan Amendment to cover awards for approximately three years, but this could vary depending on future equity grant practices, share price, and hiring activity.

Management Comments

• Richard Pilnik, Chairman of the Board, and Rick Pauls, President and Chief Executive Officer, thank shareholders for their participation, investment, and support.

Industry Context

The document benchmarks DiaMedica's executive compensation against a peer group of 20 other companies in the same industry with similar characteristics from a market capitalization, revenue, number of employees and clinical development perspective.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group of 20 companies, including Abeona Therapeutics Inc., Aceragen, Inc., and Annovis Bio, Inc.
• The company's three-year average burn rate of approximately 3.7% is lower than the industry thresholds established by certain major proxy advisory firms.

Related Party Transactions

• On April 10, 2023, in conjunction with his appointment as Chief Business Officer, David Wambeke purchased 468,750 common shares of DiaMedica at an aggregate purchase price of $750,000 or $1.60 per share.
• In June 2023, directors and officers participated in a private placement, purchasing shares at $3.91 per share.
• The company has entered into indemnification agreements with all of its directors and executive officers.

Stakeholder Impact

• Shareholders will have the opportunity to influence the company's direction through their votes on the proposals.
• Employees may be affected by changes to the incentive plan and executive compensation.
• The company's performance and governance practices can impact its relationships with customers, suppliers, and creditors.

Next Steps

• Shareholders are encouraged to vote on the proposals before the deadlines.
• The company will hold its Annual General Meeting on May 22, 2024.
• The Board and Compensation Committee will consider the outcome of the advisory votes on executive compensation when making future decisions.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Executive Compensation, Board of Directors, Incentive Plan, Shareholders, Corporate Governance, DiaMedica Therapeutics